期刊
NATURE REVIEWS DRUG DISCOVERY
卷 13, 期 11, 页码 828-851出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4389
关键词
-
资金
- US National Institutes of Health (NIH) [CA042978, CA179193, CA175747]
- Lustgarten Foundation for Pancreatic Cancer Research, USA
- Pancreatic Cancer Action Network-American Association for Cancer Research
- NIH [DPI OD006933/DP1CA174419, P50A095103-12, RC2CA148375, R01 CA157490]
- Lustgarten Foundation for Pancreatic Cancer Research
- American Cancer Society Research Scholar Grant [RSG-13-298-01-TBG]
- Lustgarten Foundation
- US National Cancer Institute Intramural Program
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据